Atty Dkt. No.: DURE-007CON2 USSN: 10/719,007

AMENDMENTS TO THE CLAIMS

Please can cancel claims 1-47 without prejudice and add new claims 48-91 as shown below. A complete listing of the claims in this case, with their status, is shown below.

1.-47. (Canceled)

- 48. (New) A method for providing analgesia in a subject, said method comprising delivering a composition comprising fentanyl or a fentanyl congener to the subject, wherein the composition is administered to the subject using a convective delivery system, is delivered from the system at a low volume rate of 2 ml/day or less and is sufficient to provide analgesia in the subject.
- 49. (New) The method of claim 48, wherein the composition is delivered using a patterned delivery regime.
- 50. (New) The method of claim 49, wherein the composition is delivered in a substantially continuous fashion.
- 51. (New) The method of claim 49, wherein the composition is delivered in a substantially uninterrupted manner for a pre-selected period of time.
- 52. (New) The method of claim 49, wherein the composition is delivered in a substantially constant fashion.
- 53. (New) The method of claim 49, wherein the composition is delivered over an extended period of time.
- 54. (New) The method of claim 53, wherein the composition is delivered for a period from about 2 to about 48 hours.

USSN: 10/719,007

55. (New) The method of claim 53, wherein the composition is delivered for a period from about 2 to 5 days.

- 56. (New) The method of claim 53, wherein the composition is delivered for a period of at least about 100 days.
- 57. (New) The method of claim 49, wherein the composition is delivered using a controlled drug delivery device.
- 58. (New) The method of claim of claim 57, wherein the controlled delivery device is implanted in the subject's body.
- 59. (New) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about $0.01 \,\mu\text{l/day}$ to about $100 \,\mu\text{l/day}$.
- 60. (New) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.04 μ l/day to about 10 μ l/day.
- 61. (New) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.2 μ l/day to about 5 μ l/day.
- 62. (New) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.5 μ l/day to about 1 μ l/day.
- 63. (New) A method for providing analgesia in a subject, said method comprising delivering to the subject a composition comprising fentanyl or a fentanyl congener, wherein said fentanyl or fentanyl congener is present in the composition at a concentration of about 0.5 mg/ml to about 500 mg/ml or greater, and further wherein the composition is administered to the subject using a convective delivery system, is delivered from the system at a low volume rate of about 2 ml/day or less and is sufficient to provide analgesia in the subject.

USSN: 10/719,007

64. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is in solution.

65. (New) The method of claim 64, wherein the fentanyl or fentanyl congener is dissolved in

a liquid carrier.

66. (New) The method of claim 63, wherein the composition is administered to the subject as

a semi-solid, gel, liquid, suspension, emulsion or an osmotic dosage pharmaceutical formulation.

67. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is present in

the composition at a concentration of at least about 2 to at least about 10,000 times greater than the

solubility of fentanyl or fentanyl congener in aqueous solution.

68. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is present in

the composition at a concentration of from about 0.5 mg/ml to about 500 mg/ml.

69. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is present in

the composition at a concentration of from about 1 mg/ml to about 400 mg/ml.

70. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is present in

the composition at a concentration of from about 50 mg/ml to about 400 mg/ml.

71. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is present in

the composition at a concentration of from about 75 mg/ml to about 300 mg/ml.

72. (New) The method of claim 63, wherein the fentanyl or fentanyl congener is present in

the composition at a concentration of from about 100 mg/ml to about 250 mg/ml.

73. (New) The method of claim 63, wherein the composition is delivered at a low volume

rate of 2 ml/day or less.

4

USSN: 10/719,007

74. (New) The method of claim 63, wherein the composition is delivered using a patterned delivery regime.

- 75. (New) The method of claim 74, wherein the composition is delivered in a substantially continuous fashion.
- 76. (New) The method of claim 74, wherein the composition is delivered in a substantially uninterrupted manner for a pre-selected period of time.
- 77. (New) The method of claim 74, wherein the composition is delivered in a substantially constant fashion.
- 78. (New) The method of claim 74, wherein the composition is delivered over an extended period of time.
- 79. (New) The method of claim 78, wherein the composition is delivered for a period from about 2 to about 48 hours.
- 80. (New) The method of claim 78, wherein the composition is delivered for a period from about 2 to 5 days.
- 81. (New) The method of claim 78, wherein the composition is delivered for a period of at least about 100 days.
- 82. (New) The method of claim 74, wherein the composition is delivered using a controlled drug delivery device.
- 83. (New) The method of claim of claim 82, wherein the controlled delivery device is implanted in the subject's body.

USSN: 10/719,007

- 84. (New) A method for providing analgesia in a subject, said method comprising delivering to the subject a composition comprising fentanyl or a fentanyl congener, wherein the composition is administered to the subject using a convective delivery system, the composition is delivered from the system at a low volume rate sufficient to deliver from about 0.01 μ g/hour to about 200 μ g/hour of the fentanyl or fentanyl congener to the subject, and further wherein said amount of delivered fentanyl or fentanyl congener is sufficient to establish a systemic analgesic effect in the subject.
 - 85. (New) The method of claim 84, wherein the fentanyl or fentanyl congener is in solution.
- 86. (New) The method of claim 85, wherein the fentanyl or fentanyl congener is dissolved in a liquid carrier.
- 87. (New) The method of claim 84, wherein the composition is administered to the subject as a semi-solid, gel, liquid, suspension, emulsion or an osmotic dosage pharmaceutical formulation.
- 88. (New) The method of claim 84, wherein the systemic analgesic effect is sufficient to manage pain in the subject.
- 89. (New) The method of claim 84, wherein the systemic analgesic effect is sufficient to treat pain in the subject.
- 90. (New) The method of claim 84, wherein the systemic analgesic effect is sufficient to modulate pain response in the subject.
- 91. (New) The method of claim 84, wherein the systemic analgesic effect is sufficient to ameliorate or alleviate pain in the subject.